Tolerability
51
7
8
34
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.9%
2 terminated out of 51 trials
94.4%
+7.9% vs benchmark
6%
3 trials in Phase 3/4
26%
9 of 34 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 34 completed trials
Clinical Trials (51)
A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)
A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults
A Study of GensSci098 in Subjects With Graves' Disease
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet
A Phase 1 Study of Y-3 in US Healthy Volunteers.
Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
Evaluation of Safety and Human Tolerance of Oral Probiotic Streptococcus Salivarius eK12
Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
Single Ascending Dose and Multiple Ascending Dose Study of AVR-48
Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects
SB17170 Phase1 Trial in Healthy Volunteer